Allurion Technologies Inc. (ALUR)
NYSE: ALUR · IEX Real-Time Price · USD
1.260
+0.140 (12.50%)
At close: Jul 2, 2024, 4:00 PM
1.240
-0.020 (-1.59%)
After-hours: Jul 2, 2024, 7:48 PM EDT
Company Description
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight.
Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Allurion Technologies Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 501 |
| CEO | Dr. Shantanu K. Gaur M.D. |
Contact Details
Address: 11 Huron Dr Ste 200 Natick, Massachusetts 01760 United States | |
| Phone | 508-647-4000 |
| Website | allurion.com |
Stock Details
| Ticker Symbol | ALUR |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001964979 |
| CUSIP Number | 02008G102 |
| ISIN Number | US02008G1022 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shantanu K. Gaur M.D. | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Samuel G. Levy | Co-Founder |
| Christopher Geberth | Chief Financial Officer and Treasurer |
| Dr. Ram Chuttani M.D. | MD, Chief Medical Officer and Founding Partner |
| Brendan Michael Gibbons | Chief Legal Officer and Corporate Secretary |
| Matt Wright | Vice President of People |
| Joyce Johnson | Senior Vice President of RA and QA |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jul 1, 2024 | 424B3 | Prospectus |
| Jul 1, 2024 | 424B3 | Prospectus |
| Jul 1, 2024 | 8-K | Current Report |
| Jun 28, 2024 | EFFECT | Notice of Effectiveness |
| Jun 28, 2024 | 424B4 | Prospectus |
| Jun 26, 2024 | EFFECT | Notice of Effectiveness |
| Jun 26, 2024 | EFFECT | Notice of Effectiveness |
| Jun 26, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 26, 2024 | 8-K | Current Report |